Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394912 | 1.00 | OPRM1 (0.38) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL13394889 | 1.00 | OPRM1 (0.38) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL13394902 | 0.90 | CYP11B1 (0.38) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL13529090 | 0.90 | CYP11B1 (0.38) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL3173342 | 0.90 | CYP11B1 (0.38) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL13395080 | 0.89 | OPRM1 (0.39) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL3168317 | 0.89 | OPRM1 (0.39) | OPRM1OPRK1KCNH2SIRT1CHRM1 | |
| SCHEMBL13395096 | 0.86 | OPRM1 (0.37) | OPRM1OPRK1KCNH2 | |
| SCHEMBL3178824 | 0.86 | OPRM1 (0.37) | OPRM1OPRK1KCNH2 | |
| SCHEMBL5112952 | 0.85 | L3MBTL1 (0.41) | SIRT1MAPK1TRPV6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | claimed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | claimed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | claimed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | claimed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | COATS STEVEN J | 2009-02-12 | — | — | US | disclosed |
| US-7439239-B2 | Tricyclic δ- opioid modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-10-21 | — | — | US | disclosed |
| EP-1833826-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069276-A2 | TRICYCLIC ō-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885OPRK1 2/4885KCNH2 623/4885 |
| US-20060135763-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885OPRK1 2/4885KCNH2 618/4885 |
| US-20090042871-A1 | Tricyclic Delta-Opioid Modulators | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885OPRK1 2/4885KCNH2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.